Spyre Therapeutics, Inc. 8-K

What Happened

• Spyre Therapeutics, Inc. announced its financial results for the fourth quarter and fiscal year ended December 31, 2025 in a press release dated February 19, 2026. The company furnished that press release as Exhibit 99.1 to a Form 8-K filed the same day under Item 2.02 (Results of Operations and Financial Condition). The Form 8-K was signed by Chief Financial Officer Scott Burrows.

Key Details

• Filing date: February 19, 2026 (Form 8-K, Item 2.02)
• Reporting period: Fourth quarter and fiscal year ended December 31, 2025
• Press release: Furnished as Exhibit 99.1 to the Form 8-K
• Form signed by: Scott Burrows, Chief Financial Officer

Why It Matters

• The 8-K signals that Spyre has released its latest earnings and annual financial summary; investors should read the Exhibit 99.1 press release for specific figures (revenue, net income/loss, cash position, and any management commentary or guidance). These results provide updated information on the company’s financial performance for 2025 and can influence investor decisions and market reaction. For more detailed audited financial statements and disclosures, consult the company’s subsequent SEC filings (e.g., the annual report).